| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6065222 | Journal of Allergy and Clinical Immunology | 2013 | 16 Pages |
Abstract
Single-dose intravenous and multiple-dose subcutaneous benralizumab reduced eosinophil counts in airway mucosa/submucosa and sputum and suppressed eosinophil counts in bone marrow and peripheral blood. The safety profile supports further development. Additional studies are needed to assess the clinical benefit in asthmatic patients.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Michel MD, David L. MD, Gail PhD, Richard MD, PhD, Ron MD, Rohit MD, William W. MD, Sally MD, Yanping PhD, Vivekananda MD, PhD, Roland PhD, Nestor A. MD, MSc,